Atea Pharmaceuticals, Inc. (AVIR) DCF Valuation

Atea Pharmaceuticals, Inc. (AVIR) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Atea Pharmaceuticals, Inc. (AVIR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore Atea Pharmaceuticals, Inc. (AVIR) financial outlook with our user-friendly DCF Calculator! Enter your assumptions for growth, margins, and expenses to calculate the intrinsic value of Atea Pharmaceuticals, Inc. (AVIR) and refine your investment approach.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 48.6 351.4 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 622.49 -100 0 0 0 0 0 0
EBITDA -14.6 -11.0 138.4 -110.8 -119.6 .0 .0 .0 .0 .0
EBITDA, % 100 -22.64 39.39 100 100 63.35 63.35 63.35 63.35 63.35
Depreciation .0 .0 .0 .3 .4 .0 .0 .0 .0 .0
Depreciation, % 100 0.03906812 0.00825348 100 100 60.01 60.01 60.01 60.01 60.01
EBIT -14.6 -11.0 138.4 -111.1 -120.0 .0 .0 .0 .0 .0
EBIT, % 100 -22.68 39.38 100 100 63.34 63.34 63.34 63.34 63.34
Total Cash 21.7 850.1 764.4 646.7 578.1 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 5.8 .0 .0 .0
Account Receivables, % 100 11.96 0 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 0 0 100 100 60 60 60 60 60
Accounts Payable .5 .1 4.5 2.6 4.3 .0 .0 .0 .0 .0
Accounts Payable, % 100 0.12337 1.29 100 100 60.28 60.28 60.28 60.28 60.28
Capital Expenditure .0 .0 .0 -1.9 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 -0.05346164 -0.00113841 100 100 -0.01092001 -0.01092001 -0.01092001 -0.01092001 -0.01092001
Tax Rate, % -0.75442 -0.75442 -0.75442 -0.75442 -0.75442 -0.75442 -0.75442 -0.75442 -0.75442 -0.75442
EBITAT -14.0 -10.9 121.0 -107.8 -120.9 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -13.4 -17.3 131.3 -111.4 -118.8 -4.3 .0 .0 .0 .0
WACC, % 5.38 5.39 5.38 5.38 5.39 5.38 5.38 5.38 5.38 5.38
PV UFCF
SUM PV UFCF -4.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -141
Equity Value 137
Diluted Shares Outstanding, MM 83
Equity Value Per Share 1.65

What You Will Get

  • Real Atea Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Atea Pharmaceuticals, Inc. (AVIR).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit Atea's specific needs.
  • Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Atea's fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections tailored for Atea Pharmaceuticals, Inc. (AVIR).
  • Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility for Atea's financial analysis.

Key Features

  • Pre-Loaded Data: Atea Pharmaceuticals' historical financial statements and pre-filled forecasts.
  • Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
  • Instant Results: View Atea Pharmaceuticals' intrinsic value recalculated in real time.
  • Clear Visual Outputs: Dashboard charts present valuation results and key metrics.
  • Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.

How It Works

  • 1. Download the Model: Obtain and open the Excel file containing Atea Pharmaceuticals, Inc.'s (AVIR) financial data.
  • 2. Adjust Key Variables: Modify essential inputs such as revenue growth rates, discount rates, and research expenditures.
  • 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and net present value (NPV).
  • 4. Explore Different Scenarios: Evaluate various projections to assess a range of valuation possibilities.
  • 5. Present with Assurance: Deliver expert valuation analysis to bolster your strategic decisions.

Why Choose This Calculator for Atea Pharmaceuticals, Inc. (AVIR)?

  • Accuracy: Leverages real Atea financial data to ensure precise calculations.
  • Flexibility: Users can easily adjust and test various inputs to suit their needs.
  • Time-Saving: Avoid the complexities of creating a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
  • User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.

Who Should Use This Product?

  • Investors: Accurately assess Atea Pharmaceuticals’ fair value before making investment choices.
  • CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
  • Consultants: Easily modify the template for client valuation reports.
  • Entrepreneurs: Acquire knowledge of financial modeling practices employed by leading pharmaceutical companies.
  • Educators: Employ it as a resource to illustrate valuation techniques in the classroom.

What the Template Contains

  • Preloaded AVIR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.